Cited 34 time in
Torilin ameliorates type II collagen-induced arthritis in mouse model of rheumatoid arthritis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Endale, Mehari | - |
| dc.contributor.author | Lee, Whi Min | - |
| dc.contributor.author | Kwak, Yi-Seong | - |
| dc.contributor.author | Kim, Na-Mi | - |
| dc.contributor.author | Kim, Bok-Kyu | - |
| dc.contributor.author | Kim, Seung-Hyung | - |
| dc.contributor.author | Cho, JaeYoul | - |
| dc.contributor.author | Kim, Suk | - |
| dc.contributor.author | Park, Seung-Chun | - |
| dc.contributor.author | Yun, Bong-Sik | - |
| dc.contributor.author | Ko, Dukhwan | - |
| dc.contributor.author | Rhee, ManHee | - |
| dc.date.accessioned | 2022-12-27T00:33:42Z | - |
| dc.date.available | 2022-12-27T00:33:42Z | - |
| dc.date.issued | 2013-06 | - |
| dc.identifier.issn | 1567-5769 | - |
| dc.identifier.issn | 1878-1705 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/20657 | - |
| dc.description.abstract | Advancements in rheumatoid-arthritis-(RA) therapies have shown considerable progresses in the comprehension of disease. However, the development of new potential agents with relative safety and efficacy continues and natural compounds have been considered as alternatives to identify new entities. Since previous in-vivo data and our in-vitro findings showed that torilin has a strong anti-inflammatory property, we further investigated its effect against collagen-induced-arthritis-(CIA) in mice. CIA-induced DBA/1J mice were treated with torilin or methotrexate (MTX) for 5-weeks. Arthritis severity was evaluated by arthritic score and joint histopathology. Draining lymph node (dLN), joint and peripheral-blood mononuclear-cell (PBMC) counts, and activation/localization of T-/B-lymphocytes, dendritic cells (DCs) and neutrophils were examined by FACS analysis. Serum anti-type-II-collagen-(CII) antibody levels and cultured-splenocyte and serum cytokines were also evaluated. Torilin markedly reduced CIA-induced arthritic score, histopathology and leukocyte counts. Besides, torilin suppressed CIA-activated T-cells including CD3 +, CD3 +/CD69 +, CD8 +, CD4+ and CD4+/CD25+ in dLNs or joints. It also modified CD19 + or CD20 +/CD23 + (B-cells), MHCII +/CD11c+ (DCs) and Gr-1 +/CD1lb + (neutrophil) subpopulations. It further depressed total anti-CII-IgG, anti-CII-IgG1 and anti-CII-IgG2a antibody productions. Moreover, while IFN-gamma and IL-10 were not affected, torilin suppressed CIA-induced serum TNF-alpha, IL-1 beta and IL-6 levels. Interestingly, torilin also blocked IFN-gamma, IL-17 and IL-6 cytokines while it did not affect IL-10 but enhanced IL-4 in splenocytes. These results show that torilin attenuated arthritis severity, modified leukocyte activations in dLNs or joints, and restored serum and splenocyte cytokine imbalances. Torilin may have immunomodulatoiy and anti-inflammatory properties with the capacity to ameliorate the inflammatory response in CIA-mice. (C) 2013 Elsevier B.V. All rights reserved. | - |
| dc.format.extent | 11 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ELSEVIER SCIENCE BV | - |
| dc.title | Torilin ameliorates type II collagen-induced arthritis in mouse model of rheumatoid arthritis | - |
| dc.type | Article | - |
| dc.publisher.location | 네델란드 | - |
| dc.identifier.doi | 10.1016/j.intimp.2013.04.012 | - |
| dc.identifier.scopusid | 2-s2.0-84877796964 | - |
| dc.identifier.wosid | 000320895400016 | - |
| dc.identifier.bibliographicCitation | INTERNATIONAL IMMUNOPHARMACOLOGY, v.16, no.2, pp 232 - 242 | - |
| dc.citation.title | INTERNATIONAL IMMUNOPHARMACOLOGY | - |
| dc.citation.volume | 16 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 232 | - |
| dc.citation.endPage | 242 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Immunology | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Immunology | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordPlus | TOLL-LIKE RECEPTORS | - |
| dc.subject.keywordPlus | JAPONICA | - |
| dc.subject.keywordPlus | INHIBITION | - |
| dc.subject.keywordPlus | CELLS | - |
| dc.subject.keywordPlus | DESTRUCTION | - |
| dc.subject.keywordPlus | SUPPRESSION | - |
| dc.subject.keywordPlus | PROGRESSION | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordPlus | CYTOKINES | - |
| dc.subject.keywordPlus | TISSUE | - |
| dc.subject.keywordAuthor | Torilin | - |
| dc.subject.keywordAuthor | CIA-mice | - |
| dc.subject.keywordAuthor | Leukocytes | - |
| dc.subject.keywordAuthor | Cytokines | - |
| dc.subject.keywordAuthor | Inflammation | - |
| dc.subject.keywordAuthor | Rheumatoid arthritis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
